Bristol-Myers Squibb Co
Healthy Returns: Trump seeks to change Medicare drug price negotiations in a win for pharma
U.S. President Donald Trump speaks to the media during the annual White House Easter Egg Roll, on the South Lawn of the White House in Washington, D.C., U.S., April 21, 2025. Leah Millis | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to […]
Read More
These are the 4 biggest things we’re watching in the stock market in the week ahead
The stock market heads into Monday on a streak of volatility it just can’t seem to shake. What had been shaping up as a positive holiday-shortened week turned on a dime Wednesday when Federal Reserve Chairman Jerome Powell signaled concern that President Donald Trump ‘s tariffs could increase inflation and slow economic growth. Speaking at […]
Read More
Pharmaceutical stocks fall as Trump doubles down on tariffs threat
The Lilly Biotechnology Center in San Diego, California, on March 1, 2023. Mike Blake | Reuters Shares of drugmakers fell on Wednesday after President Donald Trump doubled down on plans to impose tariffs on pharmaceuticals imported into the U.S. Shares of U.S.-based companies Eli Lilly, AbbVie, Bristol Myers Squibb and Regeneron all fell about 4% […]
Read More
10 beaten-up stocks that are candidates for a rebound — but all are not created equal
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Markets: Stocks are struggling to hold onto gains Tuesday with the market well off its highest levels of the session. Deeply oversold conditions combined with some […]
Read More
Hard-hit Apple bounces back with the market, and an analyst is divided on our drug stocks
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Tuesday’s key moments. 1. Wall Street surged Tuesday on increased hopes of tariff deals, following a wickedly volatile session Monday. The Dow Jones Industrial Average climbed around 1,400 points, or 3.7%. The S […]
Read More
Trump’s tariffs are a new challenge for Big Pharma. Here are the best-positioned stocks
Long-standing trade agreements have largely sheltered the pharmaceutical industry from tariffs but President Donald Trump’s goal of bringing manufacturing back to the United States has put the industry in the administration’s crosshairs. Trump first floated the idea of imposing tariffs of as much as 25% on imported pharmaceuticals in mid-February. Since then, he has repeated […]
Read More
Don’t overlook the impact of pharma tariffs, says an analyst. Where we stand on Bristol Myers
The drug stock is higher over the past month while the S&P 500 has pulled back sharply. Source
Read More
We’re booking profits in a rallying rotation play and using the cash to buy 2 others on the dip
We are making a handful of more trades Tuesday. Selling 75 shares of GE Healthcare at roughly $86 each; following the trade, Jim Cramer’s Charitable Trust will own 550 shares of GEHC, decreasing its weighting to about 1.43% from about 1.62% We are buying 50 shares of TJX at roughly $116; following the trade, the […]
Read More
We’re adding to our position in a sliding stock and booking profits in a 2025 winner
We’re making a pair of trades Monday as Wall Street rallies to kick off the week. Source
Read More
Trump is unlikely to end Medicare drug price talks — here’s what that means for patients and pharma
President Donald Trump arrives in the Brady Press Briefing Room at the White House on Jan. 30, 2025 in Washington, DC. Oliver Contreras | Afp | Getty Images President Donald Trump likely won’t do away with a landmark process that allows Medicare to negotiate drug prices with manufacturers, even as he moves to erase Joe […]
Read More